blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3856714

EP3856714 - CRYSTALLINE FORMS OF N-(1 -((2-(DIMETHYLAMINO)ETHYL)AMINO)-2-M ETHYL-1 -OXOPROPAN-2-YL)-4-(4-(2-METHYL-5- (2S,3R,4R,5S,6R)-3,4,5-TRIHYDROXY-6-(METHYLTHIO)TETRAHYDRO-2H-PYRAN-2-YL)BENZYL) PHENL)BUTANAMIDE AND METHODS OF THEIR SYNTHESIS [Right-click to bookmark this link]
Former [2021/31]CRYSTALLINE FORMS OF N-(1 -((2-(DIMETHYLAMINO)ETHYL)AMINO)-2-M ETHYL-1 -OOPROPAN-2-YL)-4-(4-(2-METHYL-5- (2S,3R,4R,5S,6R)-3,4,5-TRIHYDROXY-6-(METHYLTHIO)TETRAHYDRO-2H-PYRAN-2-YL)BENZYL) PHENL)BUTANAMIDE AND METHODS OF THEIR SYNTHESIS
[2023/28]
StatusExamination is in progress
Status updated on  17.11.2023
Database last updated on 22.05.2024
FormerRequest for examination was made
Status updated on  02.07.2021
FormerThe international publication has been made
Status updated on  05.04.2020
Formerunknown
Status updated on  18.10.2019
Most recent event   Tooltip13.04.2024New entry: Application deemed to be withdrawn: despatch of communication + time limit 
Applicant(s)For all designated states
Lexicon Pharmaceuticals, Inc.
8800 Technology Forest Place
The Woodlands, TX 77381 / US
[2021/31]
Inventor(s)01 / BEDNARZ, Mark Stephen
668 Stony Hill Rd., No. 45
Yardley, Pennsylvania 19067 / US
02 / DAI, Kuangchu
2-5/F, Building No. 79, No. 90 Delin Road
Pilot Free Trade Zone Shanghai
Shanghai 200131 / CN
03 / ECKERT, Jeffrey Manning
13 West Susan Street
Hazlet, New Jersey 07730 / US
04 / LIM, Ngiap-Kie
4687 Mangrove Drive
Dublin, California 94568 / US
05 / SIROIS, Lauren
1849 Church Street Apt. 3
San Francisco, California 94131 / US
06 / WU, Wenxue
53 Zaitz Farm Road
Princeton Junction, New Jersey 08550 / US
07 / ZHAO, Matthew Mangzhu
1 Whittier Street
Edison, New Jersey 08820 / US
 [2021/31]
Representative(s)Abel & Imray LLP
Westpoint Building
James Street West
Bath BA1 2DA / GB
[N/P]
Former [2021/31]Abel & Imray
Westpoint Building
James Street West
Bath BA1 2DA / GB
Application number, filing date19783783.423.09.2019
[2021/31]
WO2019US52414
Priority number, dateUS201862736871P26.09.2018         Original published format: US 201862736871 P
[2021/31]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2020068661
Date:02.04.2020
Language:EN
[2020/14]
Type: A1 Application with search report 
No.:EP3856714
Date:04.08.2021
Language:EN
The application published by WIPO in one of the EPO official languages on 02.04.2020 takes the place of the publication of the European patent application.
[2021/31]
Search report(s)International search report - published on:EP02.04.2020
ClassificationIPC:C07D207/16, C07C15/00, C07D309/10, C07D493/04
[2021/31]
CPC:
C07D207/16 (EP,IL,KR,US); C07D309/10 (EP,IL,KR,US); A61K31/401 (KR);
A61P3/10 (KR); C07C237/22 (EP,IL,KR); C07D493/04 (EP,IL,KR);
C07F5/025 (KR); C07B2200/13 (IL,KR,US) (-)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2021/31]
TitleGerman:KRISTALLINE FORMEN VON N-(1-((2-(DIMETHYLAMINO)ETHYL)AMINO)-2-M-ETHYL-1-OXOPROPAN-2-YL)-4-(4-(2-METHYL-5-(2S,3R,4R,5S,6R)-3,4,5-TRIHYDROXY-6-(METHYLTHIO)TETRAHYDRO-2H-PYRAN-2-YL)BENZYL) PHENL)BUTANAMID UND VERFAHREN ZU IHRER SYNTHESE[2023/28]
English:CRYSTALLINE FORMS OF N-(1 -((2-(DIMETHYLAMINO)ETHYL)AMINO)-2-M ETHYL-1 -OXOPROPAN-2-YL)-4-(4-(2-METHYL-5- (2S,3R,4R,5S,6R)-3,4,5-TRIHYDROXY-6-(METHYLTHIO)TETRAHYDRO-2H-PYRAN-2-YL)BENZYL) PHENL)BUTANAMIDE AND METHODS OF THEIR SYNTHESIS[2023/28]
French:FORMES CRISTALLINES DE N-(1 -((2-(DIMÉTHYLAMINO)ÉTHYL)AMINO)-2-M ÉTHYL-1 -OXOPROPAN-2-YL)-4-(4-(2-MÉTHYL-5- (2S,3R,4R,5S,6R)-3,4,5-TRIHYDROXY-6-(MÉTHYLTHIO)TÉTRAHYDRO-2H-PYRAN-2-YL)BENZYL) PHÉNYL)BUTANAMIDE ET PROCÉDÉS DE SYNTHÈSE ASSOCIÉS[2023/28]
Former [2021/31]KRISTALLINE FORMEN VON N-(1-((2-(DIMETHYLAMINO)ETHYL)AMINO)-2-M-ETHYL-1-OOPROPAN-2-YL)-4-(4-(2-METHYL-5-(2S,3R,4R,5S,6R)-3,4,5-TRIHYDROXY-6-(METHYLTHIO)TETRAHYDRO-2H-PYRAN-2-YL)BENZYL) PHENL)BUTANAMID UND VERFAHREN ZU IHRER SYNTHESE
Former [2021/31]CRYSTALLINE FORMS OF N-(1 -((2-(DIMETHYLAMINO)ETHYL)AMINO)-2-M ETHYL-1 -OOPROPAN-2-YL)-4-(4-(2-METHYL-5- (2S,3R,4R,5S,6R)-3,4,5-TRIHYDROXY-6-(METHYLTHIO)TETRAHYDRO-2H-PYRAN-2-YL)BENZYL) PHENL)BUTANAMIDE AND METHODS OF THEIR SYNTHESIS
Former [2021/31]FORMES CRISTALLINES DE N-(1 -((2-(DIMÉTHYLAMINO)ÉTHYL)AMINO)-2-M ÉTHYL-1 -OOPROPAN-2-YL)-4-(4-(2-MÉTHYL-5- (2S,3R,4R,5S,6R)-3,4,5-TRIHYDROXY-6-(MÉTHYLTHIO)TÉTRAHYDRO-2H-PYRAN-2-YL)BENZYL) PHÉNYL)BUTANAMIDE ET PROCÉDÉS DE SYNTHÈSE ASSOCIÉS
Entry into regional phase23.04.2021National basic fee paid 
23.04.2021Designation fee(s) paid 
23.04.2021Examination fee paid 
Examination procedure23.04.2021Amendment by applicant (claims and/or description)
23.04.2021Examination requested  [2021/31]
23.04.2021Date on which the examining division has become responsible
20.11.2023Despatch of a communication from the examining division (Time limit: M04)
12.04.2024Despatch of communication that the application is deemed to be withdrawn, reason: reply to the communication from the examining division not received in time
Fees paidRenewal fee
11.09.2021Renewal fee patent year 03
11.08.2022Renewal fee patent year 04
24.08.2023Renewal fee patent year 05
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Cited inInternational search[I]WO2014081660  (LEXICON PHARMACEUTICALS INC [US]) [I] 1-5,20,24-28 * page 61; claims 1-20; compounds 13, B *;
 [XP]  - LAUREN E. SIROIS ET AL, "Process Development for a Locally Acting SGLT1 Inhibitor, LX2761, Utilizing sp 3 -sp 2 Suzuki Coupling of a Benzyl Carbonate", ORGANIC PROCESS RESEARCH AND DEVELOPMENT, US, (20181224), vol. 23, no. 1, doi:10.1021/acs.oprd.8b00325, ISSN 1083-6160, pages 45 - 61, XP055636549 [XP] 1-5,20,24-28 * scheme 12, LX2761 L-proline co-crystal *

DOI:   http://dx.doi.org/10.1021/acs.oprd.8b00325
 [A]  - MINO R CAIRA ED - MONTCHAMP JEAN-LUC, "CRYSTALLINE POLYMORPHISM OF ORGANIC COMPOUNDS", TOPICS IN CURRENT CHEMISTRY; [TOPICS IN CURRENT CHEMISTRY], SPRINGER, BERLIN, DE, vol. 198, doi:10.1007/3-540-69178-2_5, ISSN 0340-1022, (19980101), pages 163 - 208, (19990226), XP001156954 [A] 1-5,20,24-28 * page 165 - page 166 *

DOI:   http://dx.doi.org/10.1007/3-540-69178-2_5
by applicantUS3674836
 US3983140
 US4027009
 US4231938
 US4346227
 US4448784
 US4450171
 US4499289
 EP0142146
 WO8603488
 US4613610
 WO8607054
 US4647576
 EP0221025
 US4681893
 US4686237
 FR2596393
 US4759923
 GB2205837
 US4871721
 US4924024
 US5006530
 US5011930
 US5177080
 US5260440
 US5273995
 US5354772
 US5385929
 US5488064
 US5491134
 US5506219
 US5541204
 WO9638144
 US5594016
 US5595872
 US5612359
 US5614492
 WO9712615
 WO9712613
 WO9721993
 US5686104
 US5691322
 US5712279
 US5712396
 US5739135
 US5753675
 US5760246
 US5770615
 US5776983
 US5827875
 WO9900353
 US5885983
 WO9938501
 WO9946272
 US5962440
 WO9961431
 WO9967279
 WO9967278
 WO0001389
 US6043265
 WO0121602
 WO0168603
 US6395767
 WO03033671
 US6653314
 US9200025
    - S. L. MORISETTE et al., Proc. Natl. Acad. Sci. USA., vol. 100, no. 5, pages 2180 - 84
    - A. GOHO, Science News, (20040000), vol. 166, no. 8, pages 122 - 123
    - MURAKAMI et al., Diabetes, (19980000), vol. 2010, pages 1841 - 1847
    - HUGHES et al., Biochemistry, (19990000), vol. 38, no. 36, pages 11597 - 11603
    - YAMADA et al., Bioorg. & Med. Chem. Lett., (19980000), vol. 8, pages 1537 - 1540
    - ASHWORTH et al., Bioorg. & Med. Chem. Lett., (19960000), vol. 6, no. 22, pages 1163 - 1166,2745-2748
    - BILLER et al., J. Med. Chem., (19880000), vol. 31, no. 10, pages 1869 - 1871
    - BILLER, S. A. et al., Current Pharmaceutical Design, (19960000), vol. 2, pages 1 - 40
    - P. ORTIZ DE MONTELLANO et al., J. Med. Chem., (19770000), vol. 20, pages 243 - 249
    - COREYVOLANTE, J. Am. Chem. Soc., (19760000), vol. 98, pages 1291 - 1293
    - MCCLARD, R. W. et al., J.A.C.S., (19870000), vol. 109, page 5544
    - CAPSON, T. L., PhD dissertation, Dept. Med. Chem. U of Utah, (19870600), pages 16,17,40 - 43,48-51
    - Drugs of the Future, (19990000), vol. 24, pages 425 - 430
    - NICOLOSI et al., Atherosclerosis (Shannon, Irel, (19980000), vol. 137, no. 1, pages 77 - 85
    - GHISELLIGIANCARLO, Cardiovasc. Drug Rev., (19980000), vol. 16, no. 1, pages 16 - 30
    - SMITH, C. et al., Bioorg. Med. Chem. Lett., (19960000), vol. 6, no. 1, pages 47 - 50
    - STOUT et al., Chemtracts: Org. Chem., (19950000), vol. 8, no. 6, pages 359 - 62
    - SLISKOVIC et al., Curr. Med. Chem., (19940000), vol. 1, no. 3, pages 204 - 25
    - Atherosclerosis, (19950000), vol. 115, pages 45 - 63
    - J. Med. Chem., (19980000), vol. 41, page 973
    - SENDOBRY et al., Brit. J. Pharmacology, (19970000), vol. 120, pages 1199 - 1206
    - CORNICELLI et al., Current Pharmaceutical Design, (19990000), vol. 5, pages 11 - 20
 US19990391053
 US20000519079
 US20070899641
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.